Randomized trial of two versus four years of adjuvant tamoxifen (AT) for postmenopausal women with node positive breast cancer

被引：0

作者：

Gallen, M ^{[1
]}

Alonso, C ^{[1
]}

Ojeda, B ^{[1
]}

Viladiu, P ^{[1
]}

Beltran, M ^{[1
]}

Borras, J ^{[1
]}

Pelegri, A ^{[1
]}

Tusquets, I ^{[1
]}

Barnadas, A ^{[1
]}

Arcusa, A ^{[1
]}

Bastus, R ^{[1
]}

Balil, A ^{[1
]}

Batiste-Alentorn, E ^{[1
]}

Boleda, M ^{[1
]}

Badia, MA ^{[1
]}

Garau, I ^{[1
]}

Guash, I ^{[1
]}

机构：

[1] Hosp Mar, Barcelona, Spain

来源：

EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷

关键词：

D O I：

10.1016/S0959-8049(97)89318-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P101

引用

页码：S40 / S40

页数：1

共 50 条

[31] The ATAC ('Arimidex' Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PMI) women
Tobias, JS
EUROPEAN JOURNAL OF CANCER, 2002, 38 : S92 - S92
[32] Quality of life in the intergroup exemestane study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer
Fallowfield, LJ
Bliss, JM
Porter, LS
Price, MH
Snowdon, CF
Jones, SE
Coombes, RC
Hall, E
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 910 - 917
[33] ENDOCRINE EFFECTS OF ADJUVANT LETROZOLE VERSUS TAMOXIFEN IN POSTMENOPAUSAL EARLY BREAST CANCER PATIENTS: DATA FROM THE HOBOE RANDOMIZED TRIAL
Rossi, E.
Morabito, A.
Di Rella, F.
Gravina, A.
Labonia, V.
Landi, G.
Nuzzo, F.
Pacilio, C.
Piccirillo, M. C.
de Matteis, A.
ANNALS OF ONCOLOGY, 2008, 19 : 80 - 80
[34] Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group for Cancer Evaluation study of adjuvant treatment in breast cancer 01
Sacco, M
Valentini, M
Belfiglio, M
Pellegrini, F
De Berardis, G
Franciosi, M
Nicolucci, A
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2276 - 2281
[35] CARDIAC AND THROMBOEMBOLIC MORBIDITY AMONG POSTMENOPAUSAL WOMEN WITH EARLY-STAGE BREAST-CANCER IN A RANDOMIZED TRIAL OF ADJUVANT TAMOXIFEN
RUTQVIST, LE
MATTSSON, A
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (17) : 1398 - 1406
[36] Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
Phillips, Kelly-Anne
Ribi, Karin
Sun, Zhuoxin
Stephens, Alisa
Thompson, Alastair
Harvey, Vernon
Thuerlimann, Beat
Cardoso, Fatima
Pagani, Olivia
Coates, Alan S.
Goldhirsch, Aron
Price, Karen N.
Gelber, Richard D.
Bernhard, Juerg
BREAST, 2010, 19 (05): : 388 - 395
[37] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
Goss, PE
Ingle, JN
Martino, S
Robert, NJ
Muss, HB
Piccart, MJ
Castiglione, M
Tu, D
Shepherd, LE
Pritchard, KI
Livingston, RB
Davidson, NE
Norton, L
Perez, EA
Abrams, JS
Therasse, P
Palmer, MJ
Pater, JL
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19): : 1793 - 1802
[38] Exemestane after two to three years of tamoxifen in postmenopausal women with curable breast cancer
Delozier, T
BULLETIN DU CANCER, 2004, 91 (7-8) : 581 - 581
[39] RANDOMIZED TRIAL OF ADJUVANT TAMOXIFEN COMBINED WITH POSTOPERATIVE RADIATION-THERAPY OR ADJUVANT CHEMOTHERAPY IN POSTMENOPAUSAL BREAST-CANCER
RUTQVIST, LE
CEDERMARK, B
GLAS, U
JOHANSSON, H
ROTSTEIN, S
SKOOG, L
SOMELL, A
THEVE, T
WILKING, N
ASKERGREN, J
HJALMAR, ML
CANCER, 1990, 66 (01) : 89 - 96
[40] Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M
Buzdar, AU
Cuzick, J
Forbes, J
Houghton, J
Klijn, JGM
Sahmoud, T
LANCET, 2002, 359 (9324): : 2131 - 2139

← 1 2 3 4 5 →